Halozyme Therapeutics, Inc. (HALO) operating KPIs
HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 13/3087% above fair value
$130.91−0.27 (-0.21%)
Close on Oct 30, 2026Market cap $14.86BP/E 38.6Yield –
KPIs
Operating metrics that drive Halozyme Therapeutics's business
Coming soon
This tab will track the numbers specific to Halozyme Therapeutics's business model — such as store count, revenue by banner, revenue per store and new openings — taken from filings and earnings releases.